BDRX Biodexa Pharmaceuticals Plc IFRS Annual reports only
Pharmaceutical Preparations · Nasdaq · SEC CIK 1643918 · Reporting currency GBP · Fiscal year ends 12/31
Financial factors as of 2023-12-31 (FY2023), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: GBP | FY2025*2025-12-31 | FY2024*2024-12-31 | FY2023*2023-12-31 | FY2022*2022-12-31 | FY2021*2021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | 381,000 | 699,000 | 578,000 |
| R&D expense | 3.96M | 5.44M | 4.07M | 5.11M | 4.65M |
| Operating income | -8.64M | -9.20M | -8.01M | -8.93M | -7.00M |
| Interest expense | 229,000 | 165,000 | 41,000 | 53,000 | 44,000 |
| Pretax income | -6.49M | -5.98M | -7.49M | -8.49M | -6.11M |
| Income tax | -105,000 | -250,000 | -406,000 | -832,000 | -646,000 |
| Net income | -6.38M | -5.73M | -7.08M | -7.66M | -5.46M |
| EPS (basic) | -0.00 | -0.00 | -0.02 | -1.55 | — |
| EPS (diluted) | -0.00 | -0.00 | -0.02 | -1.55 | — |
| Balance sheet | |||||
| Cash & equivalents | 8.53M | 1.67M | 5.97M | 2.84M | 10.06M |
| Receivables | 3.79M | 6.57M | 637,000 | 1.01M | 1.03M |
| Current assets | 12.44M | 8.81M | 7.03M | 4.69M | 11.76M |
| PP&E, netmay include right-of-use assets (IFRS) | 91,000 | 324,000 | 571,000 | 831,000 | 1.15M |
| Total assets | 18.18M | 14.78M | 10.54M | 5.53M | 12.91M |
| Current liabilities | 6.13M | 5.03M | 5.57M | 1.90M | 1.84M |
| Short-term debt | 61,000 | 609,000 | 169,000 | 161,000 | 146,000 |
| Long-term debt | — | 118,000 | 295,000 | 463,000 | 620,000 |
| Total debt | — | 727,000 | 464,000 | 624,000 | 766,000 |
| Total liabilities | 6.77M | 6.46M | 5.86M | 2.36M | 2.46M |
| Shareholders' equity | 11.40M | 8.32M | 4.68M | 3.16M | 10.45M |
| Net debt | — | -942,000 | -5.51M | -2.21M | -9.29M |
| Shares outstanding | — | — | — | — | 6.74B |
| Cash flow statement | |||||
| Operating cash flow | -5.59M | -12.26M | -6.83M | -7.05M | -6.01M |
| Capital expenditure | 2,000 | 9,000 | 26,000 | 62,000 | 320,000 |
| Free cash flow | -5.59M | -12.27M | -6.85M | -7.11M | -6.33M |
| Investing cash flow | -583,000 | -598,000 | -265,000 | -220,000 | -278,000 |
| Financing cash flow | 13.04M | 8.56M | 10.23M | 47,000 | 8.80M |
| Stock-based compensation | 170,000 | 283,000 | 28,000 | 123,000 | 89,000 |
Free plan shows the latest 5 periods; Pro shows all 11 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· This company does not report gross profit in XBRL.
· Amounts are in the company's reporting currency, GBP, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.